Press Releases

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026
Verastem Oncology to Present at Upcoming Investor Conferences
May 12, 2026
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 8, 2026
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 7, 2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
April 10, 2026
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
March 17, 2026
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
March 17, 2026